Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Deferred Taxes: 2011-2024

Historic Deferred Taxes for Ligand Pharmaceuticals (LGND) over the last 14 years, with Dec 2024 value amounting to $15.8 million.

  • Ligand Pharmaceuticals' Deferred Taxes fell 1170.52% to -$21.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $579,000, marking a year-over-year increase of 131.69%. This contributed to the annual value of $15.8 million for FY2024, which is 235.09% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Deferred Taxes of $15.8 million as of FY2024, which was up 235.09% from -$11.7 million recorded in FY2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Deferred Taxes peaked at $19.1 million during FY2020, and registered a low of -$20.7 million during FY2022.
  • Moreover, its 3-year median value for Deferred Taxes was -$11.7 million (2023), whereas its average is -$5.5 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Deferred Taxes tumbled by 340.46% in 2022, and later soared by 235.09% in 2024.
  • Yearly analysis of 5 years shows Ligand Pharmaceuticals' Deferred Taxes stood at $19.1 million in 2020, then crashed by 54.77% to $8.6 million in 2021, then crashed by 340.46% to -$20.7 million in 2022, then skyrocketed by 43.56% to -$11.7 million in 2023, then surged by 235.09% to $15.8 million in 2024.